Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

May 30th 2025

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia

May 30th 2025

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer

May 30th 2025

China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.

Fifteen-Year Follow-Up Data Confirm Rituximab Delays the Need for New Treatment in Advanced Follicular Lymphoma

May 29th 2025

Rituximab monotherapy delayed the time to next treatment vs watchful waiting in advanced stage, asymptomatic, low tumor burden follicular lymphoma.

BLA Is Withdrawn for Patritumab Deruxtecan in EGFR-Mutated NSCLC

May 29th 2025

The BLA seeking the approval of patritumab deruxtecan in EGFR-mutated non–small cell lung cancer has been voluntarily withdrawn.

ORIC-944 Plus AR Inhibition Yields PSA Responses in mCRPC

May 29th 2025

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

Asciminib Shows Early Activity With Multiple TKIs in Chronic Myeloid Leukemia

May 27th 2025

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

Dr Bhat on Selecting Between Liso-Cel and Pirtobrutinib in Relapsed/Refractory CLL

May 26th 2025

Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.

Dr Bekaii-Saab on the RATIONALE-306 Study of Tislelizumab Plus Chemotherapy in Esophageal Cancer

May 26th 2025

Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia

May 25th 2025

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23rd 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer

May 23rd 2025

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Liso-Cel and Pirtobrutinib Add Options in R/R CLL, Underscoring the Importance of Proper Treatment Selection

May 23rd 2025

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.

Researchers Address the Barriers to Remote Breast Cancer Symptom Monitoring in the US

May 23rd 2025

Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.

Olutasidenib Displays High Response Rates in IDH1-Mutated AML Arising From a Prior Myeloproliferative Neoplasm

May 22nd 2025

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

Dr Fonseca on Selecting a Treatment in Relapsed/Refractory Myeloma

May 22nd 2025

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting

May 21st 2025

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.